The global antibody-mediated rejection prevention market is expected to be valued at USD 89 million in 2023 and is projected to rise at a CAGR of 16% from 2023 to 2033. A valuation of USD 528.31 million has been estimated by the end of the said decade. During the last decade, the complement system has gained prominence as a significant component of the AMR market. The primary goal of using complement inhibitors is to prevent DSA-induced allograft damage. As a result, it is expected to spur market growth.
Emerging technologies, such as genomic research and donor-specific antibody detection and definition assays, have provided significant insights into the pathophysiology and prognosis of severe antibody-mediated rejection. As a result, this aspect contributed heavily to the antibody-mediated rejection prevention industry. Antibody-mediated rejection prevention is predicted to exhibit a substantial increase due to increasing pervasiveness and the anticipated unveiling of therapeutic strategies such as Clazakizumab, Imlifidase, VIB4920, Inebilizumab-cdon, Daratumumab, and others projected timeframe. The United States had the maximum AMR occurrence population, with around 3,266 cases in 2020.
According to Penn Medicine News, the shortage of kidneys remains a public health crisis in the United States. Every year, approximately 20,000 transplants are performed, and over 90,000 people are on the waiting list for kidney transplants. Furthermore, 5,000 people die while waiting for a transplant. As a result, rising late kidney transplant failure is expected to drive industry growth over the forecast period.
The rising incidence of chronic illnesses such as cancer, and heart disease, among others, is growing significantly for biologics, which is expected to drive the monoclonal antibodies segment. Correspondingly, expanding implementations of mAb treatments for therapeutic targets, as well as increased awareness of such treatment options among patients and doctors are predicted to contribute substantially to segment growth. On the other hand, Robust advancement and research against a variety of diseases, including multiple sclerosis, rheumatoid arthritis, Crohn's disorder, and many others, has led to the creation of new therapeutics, which are expected to aid in the Immunomodulators segment's expansion. Over the projected timeframe, the immunomodulators segment is predicted to expand at a CAGR of 6.3%.
North America is expected to dominate the market. This region's prominence is credited to the rising prevalence of illnesses among the USA inhabitants. Another significant contribution to the region's growth is the existence of major players, combined with the introduction of innovative products. Europe ranks second in the market due to its investments in science and technology for the creation of efficient drugs. This, along with increased immunosuppressant sales revenue, is expected to propel the market growth during the forecast period. Furthermore, Asia Pacific is expected to experience the fastest CAGR due to the expanding number of clinical trial experiments pertaining to several drugs and the region's expanding geriatric population.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | USD 89 million |
| Anticipated Forecast Value (2033) | USD 528.31 million |
| Projected Growth Rate (2023 to 2033) | 16% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The COVID-19 pandemic hampered the production, dispersion, and manufacturing of pharmaceuticals worldwide. Furthermore, owing to social distancing, footfall in clinics and medical institutions has dropped by more than 70% throughout this pandemic, resulting in a reduction in the volume of surgical operations, clinical trials, activities for research and development, and other pursuits, all of which have hampered market growth in the historical period.
However, when the industries got back to their normal functioning some companies considerably enhanced their logistics operations, augmented their R&D capabilities, and are involved more in production management and quality assurance. According to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 14%.
An expanding geriatric population base to propel market expansion
The population with end-stage kidney impairment is getting older. Nearly half of all new patient populations are over the age of 65, and one-third are over the age of 70. As a result, late kidney transplant failure is prevalent in the elderly population, which is predicted to propel the antibody-mediated rejection prevention market throughout the forecast period.
According to a Pew Research Center report, the aged population in the United States will increase to 81 million by 2050, up from 37 million in 2005. As a consequence, this factor is anticipated to contribute to industry development.
A robust drug pipeline to aid in providing more development opportunities
Year after year, research and advancement with the goal of providing advanced patient care accelerates. Experimental studies with new or existing therapeutic agents are leading to combination treatment. It has resulted in an increase in pipeline aspirants for a variety of condition prevention strategies, including antibody-mediated rejection.
Plegridy and Daclizumab by Biogen, Ocrelizumab by Roche, and Receptors' RPC-1063 and Nerventra by Teva Pharmaceuticals, for example, are expected to be available on the market during the projected timeline. Such immunomodulators are expected to garner a significant market share in the coming years, resulting in industry growth.
Principal Consultant
Difficulties in constructing clinical trials to restrict market growth
There are obstacles to the expansion of the antibody-mediated rejection prevention market, such as difficulties in constructing clinical trials, a significant clinical burden, and the requirement for evidence-based treatment protocols.
Therapeutic approaches and Development of algorithms to detect AMR drive market growth
Few therapeutic interventions have received FDA approval in the United States. The first is belatacept, which was recently approved for the treatment of severe rejection in the United States. Belatacept impeded DSA in phase 3 trials, while there was more intense cellular refusal, renal function upgraded.
Besides that, DeKAF is an NIH-funded experimental research of late allograft failure that is being carried out at five transplant centers in the United States and two in Canada. DeKAF Genomics is a peripheral study of DeKAF that is connected to Medicare claims data for patients in the United States. As a result, this factor is expected to propel market expansion.
Furthermore, the region's dominance is due to the rising prevalence of diseases among the USA population. Another significant contributing factor to the region's expansion is the existence of key players, combined with the emergence of new products.
Increasing Medical Expenditure is Spurring Demand for Antibody-mediated Rejection Prevention
Europe ranks second in the market due to its investments in scientific and technological research for the creation of high-quality drugs. Furthermore, according to a National Institute for Health and Care Excellence article, there were 4,647 individuals on the UK kidney waitlist in March 2019, and 3,280 adult kidney-only transplants in the UK in 2018/19 (with 71% coming from deceased donors). As a result, this factor is anticipated to contribute to market growth.
Collaboration efforts by the largest pharmaceutical and clinical-stage development firms, on the other side, will provide fresh avenues for monoclonal antibody expansion, which is anticipated to contribute to market expansion.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Monoclonal Antibodies to Lead the Treatment Type of Antibody-mediated Rejection Prevention
The global monoclonal antibodies segment was worth USD 186 million in 2021, and it is expected to expand at a compound annual growth rate (CAGR) of 11% between 2023 and 2033.
Because mAbs are a potential solution for COVID-19 remediation owing to their safety and efficiency, the USA FDA has granted several antibody emergency use authorizations (EUA). As a result, these factors are anticipated to propel the monoclonal antibodies segment during the forecast period.
Hospital Segment is Estimated to Hold the Largest Share
The hospital segment is predicted to maintain a dominant position in the market throughout the forthcoming years due to a rise in hospitalization rates and hospital healthcare services. Furthermore, between 2023 and 2033, the same segment is expected to experience the fastest CAGR.
Key players in the Antibody-mediated Rejection Prevention market are CSL Behring, Hansa Biopharma, Sanofi, Talaris Therapeutics, Horizon Therapeutics, Novartis AG, Biogen, Teva Pharmaceutical Industries Ltd., Eli Lilly, and Company, Bristol-Myers & Squibb Company. Some of the recent developments are below:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 89 million |
| Market Value in 2033 | USD 528.31 million |
| Growth Rate | CAGR of 16% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023-2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Treatment, End User, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, Singapore, Thailand, Indonesia, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | CSL Behring; Hansa Biopharma; Sanofi; Talaris Therapeutics; Horizon Therapeutics; Novartis AG; Biogen; Teva Pharmaceutical Industries Ltd.; Eli Lilly and Company; Bristol-Myers & Squibb Company |
| Customization | Available Upon Request |
The global adoption of antibody-mediated rejection prevention services could register 16% CAGR through 2033.
The global sales on an average exhibited a y-o-y increment of 14% from 2018 to 2022.
The hospital segment is projected to maintain its dominance by growing at a higher CAGR through 2033.
The monoclonal antibodies segment is forecasted to expand at 11% CAGR until 2033.
Therapeutic interventions like belatacept are likely to advance the overall demand in the country.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 5.1. Monoclonal Antibodies 5.2. Cysteine Protease Inhibitors 5.3. Immunomodulators 5.4. Plasmapheresis 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 6.1. Hospitals 6.2. Specialty Clinics 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Europe 7.4. Asia Pacific 7.5. MEA 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Key Countries Market Analysis 14. Market Structure Analysis 15. Competition Analysis 15.1. CSL Behring 15.2. Hansa Biopharma 15.3. Sanofi 15.4. Talaris Therapeutics 15.5. Horizon Therapeutics 15.6. Novartis AG 15.7. Biogen 15.8. Teva Pharmaceutical Industries Ltd. 15.9. Eli Lilly and Company 15.10. Bristol-Myers & Squibb Company 16. Assumptions & Acronyms Used 17. Research Methodology
Explore Healthcare Insights
View Reports
Antibody-mediated Rejection Prevention Market
